Back to Consumer and Branded Businesses
    Consumer and Branded Businesses

    Selling a Wellness Business

    The US wellness economy exceeds $2 trillion and continues growing at rates that outpace most consumer categories. Institutional buyers, from strategic health conglomerates to PE consumer health platforms, are actively acquiring wellness brands that combine subscription economics, clinical validation, and the secular demand tailwinds driving consumer health spending. Brands with recurring revenue, defensible clinical positioning, and loyal communities are trading at the highest multiples in the consumer branded segment.

    FISART advises wellness founders through a structured sell-side process built for a category where clinical credibility, regulatory compliance, and community engagement matter as much as financial performance. A clinically validated supplement brand requires a fundamentally different buyer approach than a fitness recovery product line or a sleep technology company. That buyer matching precision is what creates competitive tension and prevents your brand from being undervalued by buyers who do not understand the wellness category.

    Schedule a Confidential Consultation

    5-9x EBITDA

    250+

    4-6 months

    $2T+

    Why institutional buyers are acquiring wellness brands

    Wellness brands attract institutional buyer attention because the category sits at the intersection of three powerful trends: secular growth in consumer health spending, the shift toward preventive and proactive health management, and the premiumization of everyday wellness products. These macro tailwinds create a demand floor that makes wellness businesses more predictable and recession-resistant than most consumer categories.

    Strategic health conglomerates acquire wellness brands to access clinical innovation, subscription-native business models, and direct consumer relationships they cannot build organically at comparable speed. A founder-led supplement brand with clinically validated products and a loyal subscriber base represents capabilities that would take a large conglomerate three to five years and significant investment to develop internally.

    PE consumer health platforms target wellness brands with margin expansion potential through shared manufacturing, consolidated regulatory compliance, and cross-selling across multi-brand portfolios. Brands with subscription revenue, clinical differentiation, and $2M or more in EBITDA are the primary acquisition targets for these platforms.

    What makes wellness brands valuable

    • Subscription or membership revenue providing predictable, recurring cash flows
    • Clinical validation or third-party certifications creating competitive barriers
    • Gross margins at 50% or higher with stable ingredient and manufacturing costs
    • Loyal community with high organic acquisition and low customer acquisition costs
    • Clean regulatory compliance with properly substantiated product claims

    How we prepare wellness businesses for institutional buyers

    Preparing a wellness business for institutional buyers demands category-specific financial presentation that goes beyond standard EBITDA analysis. Buyers want clinical evidence packages organized for diligence review, subscription cohort analysis with retention and churn curves, gross margin breakdowns by product and channel, and regulatory compliance documentation demonstrating that all claims are properly substantiated. Presenting this at institutional standards before going to market builds buyer confidence and compresses the diligence timeline significantly.

    FISART identifies the specific buyer types whose acquisition criteria align with your brand's clinical positioning, subscription model, and growth stage. A functional nutrition brand with third-party certifications belongs in front of different buyers than a mental wellness app with membership revenue. This buyer matching precision creates genuine competitive tension among acquirers who understand the wellness category.

    Our sell-side process

    • 1
      Subscription retention analysis with cohort-level churn, LTV, and payback documentation
    • 2
      Clinical evidence and certification packaging for diligence-ready presentation
    • 3
      EBITDA normalization for owner compensation, R&D spend, and regulatory costs
    • 4
      Wellness-specific buyer identification across strategic, PE, and family office segments
    • 5
      Negotiation of IP transfer, clinical claims transition, and earn-out structures

    Who buys wellness businesses

    The wellness buyer landscape includes strategic health conglomerates expanding their consumer portfolios, PE platforms building multi-brand wellness holdings, family offices with secular health investment theses, and search funds targeting category-specific operators.

    Strategic health and wellness conglomerates

    Companies like Nestle Health Science, Herbalife, and Clorox (through its health brands) acquiring wellness brands to expand their consumer health portfolios. They bring global distribution, clinical R&D capabilities, and retail relationships that accelerate growth beyond what founder-led brands can achieve independently.

    Consumer health PE platforms

    Private equity firms building wellness brand portfolios through buy-and-build strategies. They target brands with $2M or more in EBITDA, subscription revenue, and clear margin expansion paths through shared manufacturing, regulatory infrastructure, and cross-selling across the portfolio.

    Family offices with health and wellness holdings

    Privately capitalized investors who view wellness brands as long-term, secular-growth holdings. They value the combination of non-discretionary demand, subscription economics, and the demographic tailwinds driving wellness spending across all age groups.

    Search funds and independent sponsors

    Entrepreneurial acquirers targeting a single wellness brand to operate and scale. They seek businesses in the $1M to $4M EBITDA range with loyal subscriber bases, clinical differentiation, and a product line that supports natural expansion into adjacent wellness categories.

    Key valuation drivers in wellness M&A

    Subscription and membership revenue is the dominant valuation driver in wellness M&A. Brands with 35% or more recurring revenue and documented cohort-level retention data command materially higher multiples than brands dependent on one-time purchases. Buyers model subscription economics at a granular level, looking at payback periods, churn curves, and expansion revenue within existing cohorts.

    Clinical validation and regulatory compliance amplify the multiple further. Brands with published efficacy data, third-party certifications, and clean FDA and FTC compliance records trade at the upper end of the range. Community strength, measured through organic acquisition share, engagement metrics, and customer advocacy, rounds out the factors that separate 5x deals from 9x deals.

    What buyers evaluate

    • Subscription and membership revenue share
    • Clinical validation or third-party certifications
    • Customer retention rates and cohort-level LTV
    • Gross margin profile (50% or higher for premium brands)
    • Regulatory compliance and claims documentation
    • Community engagement metrics and organic customer acquisition

    Wellness segments we cover

    FISART advises wellness brands across every category and business model. Buyer groups, valuation benchmarks, and regulatory requirements vary significantly by product type and clinical positioning.

    Dietary supplements and nutraceuticals
    Functional foods and beverages
    Fitness and recovery products
    Mental wellness and stress management
    Sleep technology and sleep aids
    Alternative and integrative health brands

    Is your wellness brand a fit

    FISART typically works with wellness brands that have subscription economics, clinical differentiation, and healthy margins. Early preparation, including regulatory documentation and cohort analytics, consistently improves outcomes.

    We work with wellness brands that

    • generate $2M or more in annual revenue with subscription or recurring revenue components
    • maintain gross margins of 50% or higher across the core product line
    • hold clinical validation, third-party certifications, or proprietary formulations
    • demonstrate strong customer retention with documented cohort-level data
    • prefer a confidential, advisor-led process with category-matched buyer outreach

    Common questions about selling a wellness business

    Direct answers on wellness valuations, subscription economics, clinical validation impact, and the regulatory details institutional buyers examine during diligence.

    Wellness businesses in the lower middle market typically trade between 5x and 9x EBITDA. The wide range reflects significant variation in business model quality within the category. Brands with subscription revenue, clinical validation, and gross margins above 55% consistently trade at the upper end. Brands relying on one-time purchases, without clinical differentiation, or with heavy dependence on influencer marketing trade at the lower end. The US wellness economy exceeds $2 trillion, and institutional buyers are paying premium multiples for brands positioned in high-growth sub-segments like functional nutrition, sleep technology, and mental wellness.

    Subscription and membership revenue is the most impactful valuation driver in wellness M&A because it provides predictable, recurring cash flows that institutional buyers can model with confidence. Brands with 35% or more of revenue from subscriptions receive materially higher multiples than comparable brands relying entirely on one-time purchases. Buyers also value subscription data because it enables cohort-level analysis of retention, churn, and lifetime value, all of which feed directly into their acquisition models. Building or expanding a subscription offering 12 to 18 months before a sale is one of the highest-impact preparation steps for wellness founders.

    Clinical validation is a primary differentiator in wellness M&A because it separates defensible brands from commodity products. Brands with published efficacy studies, third-party testing certifications (NSF, USP, Informed Sport), or clinical trial data create barriers that competitors cannot easily replicate. Buyers view clinical evidence as both a marketing asset and a legal shield against regulatory risk. During diligence, buyers scrutinize whether wellness claims are properly substantiated under FTC and FDA guidelines. Brands with aggressive or unsubstantiated claims face both valuation discounts and increased transaction risk.

    Community engagement and brand loyalty are uniquely important in wellness M&A because they indicate organic demand that does not depend on paid acquisition. Buyers analyze email and SMS list health, social media engagement rates, user-generated content volume, and the share of revenue coming from organic versus paid channels. A wellness brand where 50% or more of new customers come through organic channels, word of mouth, community referrals, or content, has a fundamentally different risk and margin profile than one spending 40% of revenue on paid acquisition.

    Regulatory compliance is a gating factor in wellness transactions. Buyers review FDA registration and compliance history, FTC claims substantiation, ingredient sourcing and safety documentation, manufacturing facility certifications (GMP, NSF), and any history of warning letters, recalls, or consumer complaints. Clean regulatory records with properly documented claims are table stakes. Regulatory issues discovered during diligence, even if historically resolved, can delay transactions by months and reduce valuations by 20% or more. FISART audits all regulatory documentation early in the preparation phase to identify and address any issues before buyers surface them.

    A well-prepared wellness brand sale typically reaches a signed letter of intent within 45 to 60 days of active marketing, with full closing in 4 to 6 months from process launch. Transactions involving complex regulatory transfers, international distribution agreements, or clinical IP assignments may extend toward the longer end of that range. FISART's preparation phase before marketing, covering clinical documentation, subscription analytics, financial normalization, and buyer targeting, is designed to compress the active marketing period and prevent the diligence delays that slow many wellness transactions.

    Find the right buyer for your wellness brand

    Get a confidential assessment of your brand's clinical positioning and market value, and see which strategic buyers and consumer health platforms in our network are actively acquiring in your category.

    Schedule a Confidential Consultation